Results 191 to 200 of about 27,755 (279)

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6162-6171, July 2026.
ABSTRACT Aims Tirzepatide, an injectable glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist (RA), is approved for weight management in several regions. Oral GLP‐1 RAs, such as semaglutide, are under investigation to improve convenience, acceptance and adherence versus injectable formulations ...
Andreea Ciudin, Erin Johansson, Sarah Zimner‐Rapuch, Georgios K. Dimitriadis, Mathias Hempfling, Laura J. Clark, Ludi Fan, Helene Sapin   +7 more
wiley   +1 more source

GIP Gene [PDF]

, 2020
openaire   +1 more source

Dietary intake patterns and nutritional adequacy among adults with overweight or obesity treated with GLP-1 or dual GIP/GLP-1 receptor agonists- preliminary study. [PDF]

J Transl Med
Korus S, Cembrowska-Lech D, Kłoda K, Stachowska E.   +3 more
europepmc   +1 more source

Postprandial Glucagon Action in the Human Brain

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5926-5938, July 2026.
ABSTRACT Aims Elevated fasting glucagon is linked to hyperglycemia, but postprandial glucagon effects are less understood. Recent evidence suggests metabolic benefits of rising glucagon after oral glucose intake, potentially impacting brain‐mediated whole‐body metabolism.
Robert Wagner, Stephanie Kullmann, Julia Hummel, Katsiaryna Prystupa, Elena Hosenfeld, Ralf Veit, Andreas L. Birkenfeld, Hans‐Ulrich Häring, Hubert Preissl, Andreas Fritsche, Andreas Peter, Martin Heni   +11 more
wiley   +1 more source

Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy. [PDF]

Indian J Med Res
Gupta M, Shukla J.
europepmc   +1 more source

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6347-6357, July 2026.
ABSTRACT Aims Evidence on cardiovascular/renal outcomes associated with GLP‐1‐based therapies in type 1 diabetes (T1D) is limited. We examined the effects of GLP‐1‐based therapy on major clinical outcomes and safety, including diabetic ketoacidosis (DKA) and hypoglycemia risk, in adults with T1D in a large real‐world cohort.
Anastasios Tentolouris, Charalampos Filippatos, Nikolaos‐Iason Tepetes, Maria Gavriatopoulou, Evangelos Terpos, Alexandros Briasoulis, Kimon Stamatelopoulos, Theodosios Filippatos   +7 more
wiley   +1 more source

Epidemiological study of gastrointestinal parasites in yaks (<i>Bos grunniens</i>) from the Ganzi Tibetan autonomous prefecture, Sichuan Province, China. [PDF]

Parasite Epidemiol Control
Ahmed M, Pan Y, Wang L, Li Y, Qi J, Lan L, Zuo Z, Xie Y.   +7 more
europepmc   +1 more source

Body Composition Optimization in the Era of GLP‐1‐Based Pharmacotherapy for Obesity Management

Lifestyle Medicine, Volume 7, Issue 3, July 2026.
Grant M. Tinsley, Spencer Nadolsky, Karl Nadolsky   +2 more
wiley   +1 more source

Multidisciplinary Therapy to Target Obesity and Its Complications in Adult Population: A Narrative Review

Obesity Reviews, Volume 27, Issue 7, July 2026.
ABSTRACT Obesity as a chronic and multifactorial disease requires a multidisciplinary team acting together in a holistic multitarget intervention. Multidisciplinary therapy targeting obesity and its complications includes physical exercise, nutritional, and behavior counseling.
Ana Raimunda Dâmaso, Flávia Campos Corgosinho, Deborah Cristina Landi Masquio, Nayra Figueiredo, Fabiana Kattah, Cintia Cercato, Lian Tock, Raquel Munhoz da Silveira Campos   +7 more
wiley   +1 more source

Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders. [PDF]

Diabetes Metab Syndr Obes
Qiao Y, Zhou F, Mao T, Gao L.
europepmc   +1 more source